First, we performed global transcriptomics analysis (RNAseq) on different treatment groups (PBS, anti-PD-1 treatment, anti-PD-1 plus CD8+ depletion and anti-PD-1 plus CD4+ depletion) of the two selected syngeneic models, MC38 and Hepa1-6 tumors, for their contrasting tumor immunity. This evidence concerns the gene CD4 and neoplasm.